בשל "הגנת זכויות יוצרים", מובא להלן קישור למאמר בלבד. לקריאתו בטקסט מלא, אנא פנה לספרייה הרפואית הזמינה לך.

Serotonin 5-HT3 receptor antagonists such as ondansetron have been investigated to attenuate opioid withdrawal signs in studies.

Therefore, we designed a randomized double-blinded placebo-controlled trial to evaluate this effect in opioid-addicted patients who were admitted to orthopedic department for surgery due to bone fractures.

The vital signs and withdrawal symptoms and the frequency requirement of fentanyl were recorded during anesthesia, and opioid (pethidine) analgesic were received the period of recovery.

Outcome parameters were analyzed for reduction of withdrawal symptoms in adult addicted patients.

We indicated that ondansetron demonstrated significant differences with few vital outcomes including systolic blood pressure (BPS) 20 (BPS 3) and 50 min (BPS 4) after injection of ondansetron during the period of the surgery.

Ondansetron could also significantly reduce the frequency requirement of fentanyl at 20 min (Dose 3) in general anesthesia.